{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:09:42Z","timestamp":1792642182296,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Imaging"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jcmg.2020.07.043","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T18:06:24Z","timestamp":1603908384000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":191,"title":["Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression"],"prefix":"10.1016","volume":"14","author":[{"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Naharro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Rowczenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Gilbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol J.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetla","family":"Strehina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirusha","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Hutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmg.2020.07.043_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2020.07.043_bib2","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jcmg.2020.07.043_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2020.07.043_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2020.07.043_bib5","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2020.07.043_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1515\/CCLM.2004.108","article-title":"Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure","volume":"42","author":"Emdin","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jcmg.2020.07.043_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2020.07.043_bib8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2020.07.043_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2020.07.043_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcmg.2020.07.043_bib11","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2020.07.043_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2015141744","article-title":"Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study","volume":"277","author":"Fontana","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jcmg.2020.07.043_bib13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"14","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcmg.2020.07.043_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1532-429X-16-2","article-title":"T1-mapping in the heart: accuracy and precision","volume":"16","author":"Kellman","year":"2014","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2020.07.043_bib15","first-page":"63","article-title":"Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method","volume":"14","author":"Kellman","year":"2012","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jcmg.2020.07.043_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","article-title":"Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis","volume":"25","author":"Ross","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2020.07.043_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2020.07.043_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jcmg.2020.07.043_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcmg.2020.07.043_bib20","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcmg.2020.07.043_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jcmg.2020.07.043_bib22","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmg.2020.07.043_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcmg.2020.07.043_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis","volume":"20","author":"Gillmore","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jcmg.2020.07.043_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/13506129.2012.684810","article-title":"New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis","volume":"19","author":"Leone","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.jcmg.2020.07.043_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"}],"container-title":["JACC: Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X20308019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936878X20308019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:50:55Z","timestamp":1761846655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936878X20308019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1936878X20308019"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmg.2020.07.043","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739009873.793583161","asserted-by":"object"}]},"ISSN":["1936-878X"],"issn-type":[{"value":"1936-878X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmg.2020.07.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}